Model Answer

Antimicrobial Resistance (AMR) refers to the ability of microorganisms such as bacteria, viruses, fungi, and parasites to withstand the effects of medicines designed to kill or inhibit them. It has emerged as one of the gravest public health challenges of the 21st century. Globally, drug-resistant infections are projected to cause nearly 10 million deaths annually by 2050 if corrective measures are not undertaken. India bears a disproportionate share of this burden due to high infectious disease prevalence, widespread empirical antibiotic use, and gaps in infection control. In this context, the role of premier institutions like the All India Institute of Medical Sciences (AIIMS), New Delhi, becomes critical in addressing AMR through research, diagnostics, targeted therapies, and systemic interventions.

Advancing Early and Accurate Diagnostics

One of the key drivers of AMR in India is the empirical use of broad-spectrum antibiotics before identifying the causative pathogen. AIIMS has focused on narrowing this “diagnostic uncertainty window” by strengthening rapid and precise diagnostic capabilities. As a designated Infectious Disease Research Diagnostic Laboratory (IRDL) centre, AIIMS contributes to early detection of resistant pathogens through advanced microbiological and molecular techniques. Research on site-specific biomarkers for conditions such as sepsis and bacteremia helps clinicians initiate appropriate therapy at an early stage, thereby reducing unnecessary antibiotic exposure. Early diagnosis not only improves survival outcomes but also limits the selective pressure that accelerates resistance.

Targeted Therapies and Innovative Research

AIIMS has been at the forefront of promoting pathogen-specific and resistance-guided treatment strategies. With the increasing prevalence of ESKAPE pathogens—such as Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa—AIIMS research emphasizes rapid identification of resistance patterns to enable targeted therapy. Additionally, innovative approaches like quorum sensing inhibitors are being explored to disrupt bacterial communication systems, reducing virulence without directly killing bacteria, thereby lowering the chances of resistance development.

A notable success in targeted therapy is the BPaL-M regimen for drug-resistant tuberculosis. By combining bedaquiline, pretomanid, linezolid, and moxifloxacin, AIIMS-supported research has helped shorten treatment duration to six months with high success rates. This marks a paradigm shift from prolonged and toxic regimens, demonstrating how evidence-based innovation can address AMR in high-burden diseases.

Surveillance and National Coordination

AIIMS plays a pivotal role in AMR surveillance through coordination of the Antimicrobial Resistance Surveillance Network (AMRSN). Surveillance data generated through this network informs national treatment guidelines, identifies emerging resistance trends, and supports evidence-based policymaking. Such data is crucial for aligning clinical practice with the National Action Plan on AMR and for fulfilling India’s commitments under the Global Action Plan on AMR led by the WHO.

Strengthening Infection Control and Stewardship

Beyond laboratories and research, AIIMS contributes significantly to hospital infection control and antimicrobial stewardship. Strict adherence to hand hygiene, environmental cleaning, disinfection protocols, and isolation practices reduces the spread of resistant organisms within healthcare settings. AIIMS also promotes rational antibiotic use through stewardship programmes that guide clinicians on appropriate drug choice, dosage, and duration. These measures are essential in preventing healthcare-associated infections and curbing the amplification of resistance.

Significance for India’s Health System

The efforts led by AIIMS have wider implications for India’s health system. By reducing mortality from drug-resistant infections, lowering healthcare costs, and improving treatment outcomes, such initiatives strengthen health system resilience. They also serve as a model for other tertiary and secondary healthcare institutions to replicate best practices in diagnostics, surveillance, and infection control.

Conclusion

Antimicrobial resistance is a complex, multi-dimensional challenge that threatens decades of medical progress. Institutions like AIIMS play a central role in India’s fight against AMR by integrating cutting-edge research, rapid diagnostics, targeted therapies, surveillance, and infection control. Strengthening and scaling such institution-led efforts, along with policy support and public awareness, is indispensable for safeguarding the effectiveness of antimicrobials and ensuring sustainable public health outcomes in India.